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Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most promising therapies for hematologicD273X X
malignancies. Two CAR T products were recently approved in the United States and Europe for the treatment of patients up
to age 25 years with relapsed or refractory BD274X Xcell acute lymphoblastic leukemia D275X Xand/or adults with large BD276X Xcell lymphoma.
Many more CAR T products, as well as other immunotherapies, including various immune cell- and bi-speciﬁc antibody-
based approaches that function by activation of immune effector cells, are in clinical development for both hematologic and
solid tumor malignancies. These therapies are associated with unique toxicities of cytokine release syndrome (CRS) and
neurologicD277X Xtoxicity. The assessment and grading of these toxicities D278X XvaryD279X Xconsiderably across clinical trials and across institu-
tions, making it difﬁcult to compare the safety of different products and hindering the ability to develop optimal strategies
for management of these toxicities. Moreover, some aspects of these grading systems can be challenging to implement
D280X Xacross centers. Therefore, in an effort to harmonize the deﬁnitions and grading systems for CRS and neurotoxicity, experts
from all aspects of the ﬁeld met on June 20 and D281X X 1, 2018, at a meeting supported by the American Society for Blood and
Marrow Transplantation (ASBMT) in Arlington, VA. HereD282X Xwe report the consensus recommendations of thatD283X Xgroup and pro-
pose newdeﬁnitions and grading for CRS and neurotoxicity that are objective, easy to applyD284X X, and ultimatelymore accurately
categorize the severity of these toxicities. The goal is to provide a uniform consensus grading system for CRS and neurotox-
icity associatedwith immune effector cell therapies, for use across clinical trials and in the postD285X Xapproval clinical setting.
© 2018 American Society for Blood andMarrow Transplantation. This is an open access article under the CC BY-NC-ND
license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)Keyw D286X Xords:
Consensus grading
Cytokine release syndrome
Neurotoxicity
CAR T cell therapy
Cellular immunotherapy
Immune effector cellgments on page XXXX.
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246INTRODUCTION
Chimeric antigen receptor (CAR) T cell therapies are revolu-
tionizing the management of B D287X Xcell leukemias and lymphomas
and are quickly being extended to numerous other malignancies.
Two CD19 CAR T cell products were recently approved in the
United States and Europe [1-4]D288X X, and more indications are
expected in the coming years. Tisagenlecleucel has been D289X Xapproved
for multiply relapsed or refractory BD290X Xcell acute lymphoblastic leu-
kemia (ALL) in patients up to age 25 years, as well as for D291X Xrelapsed
or refractory large BD292X Xcell lymphoma in adults, and axicabtagene
ciloleucel has beenD293X Xapproved for D294X Xrelapsed or refractory large BD295X Xcell
lymphoma in adults. These therapies are now being tested in ear-
lier lines of treatment, signaling the growing scope of CAR ther-
apy in the management of these diseases. CAR therapies
targeting CD22 in BD296X Xcell malignancies [5] and BD297X Xcell maturation
antigen (BCMA) in multiple myeloma [6]D298X Xhave been D299X Xhighly suc-
cessful in early trials and D300X Xare also forthcoming, along with combi-
nation approaches targeting multiple antigens simultaneously.
Early clinical trials of CD19 CAR T cells quickly uncovered
greater toxicitiesD301X Xthan those seen in other cellular therapies, indi-
cating profound and generalized immune system activation.
Some of these toxicities, especially cytokine release syndrome
(CRS), were reminiscent of those seen in a study in which D302X XallD303X X6
healthyD304X X young male volunteers who received a low dose of
TGN1412 (D305X Xa superagonist monoclonal antibody to CD28)D306X Xrequired
critical care for the rapid onset of multiorgan failure [7]. Symp-
toms induced by TGN1412 includedD307X X fever, rigors, hypotension
requiring vasopressor support and other aggressive manage-
ment, tachycardia, hypoxia, respiratory failure, capillary leak,
acute kidney injury, coagulopathy, and even neurologicD308X Xmanifes-
tations, including poor concentration and delirium. Retrospective
analysis revealed marked elevations in C-reactive protein (CRP),
INF-D309X Xg D310X X, D311X XTNF-a D312X X, IL-6, IL-10, IL-2, and IL-1b, among other cytokines.
AltD313X Xhough all volunteers eventually recovered with the use of
high-dosemethylprednisolone, the IL-2 receptor antagonistD314X Xdacli-
zumab, and aggressive supportive care, the rapidity and severity
of the toxicities precluded further development of TGN1412.
Similar toxicities were observed in the initialD315X Xpatients treated
with CD19 CAR T cells. In the ﬁrst pediatric ALL patient treated
[8,9], it became clear that supraphysiologic cytokine elevation was
responsible for the vast majority of symptoms, suggesting that
these toxicities were the result of CRS. Investigators struggled with
the then-accepted deﬁnition of and grading scheme for CRS. In the
Common Terminology Criteria for Adverse Events version 3
(CTCAE v3 [10]D316X X), which was in effect when many of these studies
began, CRS onset was deﬁned as D317X Xwithin 24 hours of initiation of
therapy, which is atypical for CRS associated with CAR T cells as
well as other immune effector cellD318X Xtherapies. In CTCAE v4.03 [11]
(Table 1)D319X X, the deﬁnition did not include fever as a prerequisite for
CRS, and the grading was dependent in part on whether the drug
infusion was interruptedD320X X, a feature not applicable to CAR T cells,
whichD321X Xgenerally are infused in a single dose in D322X Xa concise time frame
(2 to D323X X 0minutes). Indeed, CTCAE v4.03wasmore applicable to tox-
icity seenwith antibody infusions rather than with cell infusions.
Without a clear and accurate consensus available, CRS grad-
ing has varied widely among D324X Xinstitutions and has evolved over
time, making toxicity comparisons between products and trials
exceedingly difﬁcult. For these reasons, and because D325X Ximmune
effector cell-associated CRS can be fatal if not recognized and
treated promptly, a CRS grading system that more accurately
captures the potentially severe syndrome observed after
immune effector cell therapies is needed. In a D326X XdditionD327X X, this CRS
grading system should have broad applicability across multiple
institutions and/or CAR products and other cellular immuno-
therapies with minimal effort for implementation.Along with D328X XCRS, another common toxicity observed after CAR
T cell therapy is neurotoxicity [12]. Immune effector cell-associ-
ated neurotoxicity syndrome (ICANS) may manifest as delirium,
encephalopathy, aphasia, lethargy, difﬁculty concentrating, agita-
tion, tremor, seizures, and, rarely, cerebral edema. In addition,
headache is very commonD329X Xand mD330X Xight not represent neurotoxicity
per se. Previously considered in aggregate with CRS, neurotoxic-
ity is now treated as a separate entity D331X Xowing to its distinct timing
and response to intervention. Neurologic symptoms may occur
during or more commonly after D332X XCRS symptoms (but rarely before
CRS), D333X XvarD334X Xy among patients, and have an unclear pathophysiology,
distinct from CRS. One challenge has been D335X Xto identifyD336X Xthe symp-
toms most relevant to neurotoxicity. Investigators have used
multiple different terms for similar symptomatology, resulting in
considerable variation in grading across trials and also across dif-
ferent D337X Xinstitutions within the same trial. For example, a patient
experiencing encephalopathy after CAR T cell therapy may be
reported as having any or a combination of the following vague,
overlapping CTCAE adverse event terms: confusion, delirium,
encephalopathy, cognitive disturbance, concentration
impairment, somnolence, andD338X Xdepressed level of consciousness
[13]. Ascertainment has changed over time and even within trials
as the issue of neurotoxicity has becoD339X Xme more apparent. More-
over, CTCAE grading of neurologicD340X Xtoxicities based on the ability
to perform instrumental and self-care activities of daily living are
not always applicable to children or for hospitalized adult CAR T
patients who may be bedridden for related coD341X Xmorbidities. The
multiple adverse event terms used to grade neurologicD342X Xtoxicities
are also not practical for application at the bedside for rapid and
dynamic assessment of patients, so discerning D343X Xthe appropriate
terms is difﬁcult and often highly subjective. Therefore, there is a
need for an objective, reproducible, D344X Xeasy-D345X Xto-D346X Xuse, and practicableD347X X
tool that can be usD348X Xed by all health care providers and possibly
caregivers to D349X XrecognizeD350X Xand assessD351X Ximmune effector cell-associated
neurologicD352X Xtoxicities in the inpatient or outpatient setting.
INITIAL ATTEMPTS TO BETTER DEFINE AND GRADE CRS
D353X XAlthough early clinical trials modiﬁed the CTCAE v4.03 grad-
ing of CRS, further reﬁnement was achieved when a multi-insti-
tutional group of pediatric oncologists leading CAR T cell trials
across the United States published what is now commonly
referred to as the Lee criteria [14]. This work reD354X Xdeﬁned the clinical
signs and symptoms associated with CRS (Table 1). Of note, neu-
rologic toxicities such as confusion, delirium, aphasia, and so onD355X X
were included but are now generally accepted to be a separate
syndrome (although cytokines have been implicated in the path-
ophysiology of this syndrome), owing to the differential time of
presentation compared to the other signs of CRS and lack of
knowledge surrounding its etiology and pathophysiology. The
new constellation of symptoms incorporated the experience
across CAR T studies in hematologic malignancies and included,
for the ﬁrst time, fever as a hallmark of CRS.
Lee and colleagues then redeﬁned the grading criteria for
CRS revolving around hypoxia requiring oxygen supplementa-
tion, hypotension, and other end-organ toxicities (Table 1)
[14]. In contradistinction to conventional CTCAE grading
schemes, hypotension responsive to low-dose vasopressors
was considered a gD356X Xrade 2 CRS. Early experience demonstrated
that reliance on i.v.D357X X ﬂuids (IVF) alone to manage persistent
hypotension was inferior to early vasopressor use owing to sig-
niﬁcant capillary leak and subsequent pulmonary edema and
effusions after IVF management, leading to a cascade of events
that can quickly result in life-threatening toxicity. Further-
more, patients who are easily managed with minimal vaso-
pressors are decidedly distinct in terms of CRS severity from
Table 1
Published CRS G D1X Xrading SD2X Xystems D3X X
Grading System D4X X Grade 1 Grade 2 Grade 3 Grade 4
CTCAE v D5X Xersion 4.03 [11] Mild reaction; infusion
interruption not indi-
cated; intervention not
indicated
Therapy or infusion interrup-
tion indicated but responds
promptly to symptomatic
treatment (antihistamines,
NSAIDs D6X X, narcotics, i.v. D7X Xﬂuids);
prophylactic medications indi-
cated for  D8X X24 h D9X X
Prolonged (eg, not rapidly respon-
sive to symptomatic medication
and/or brief interruption of infu-
sion); recurrence of symptoms fol-
lowing initial improvement;
hospitalization indicated for clini-
cal sequelae (egD10X X, renal impairment,
pulmonary inﬁltrate)
Life-threatening consequen-
ces; pressor or ventilatory
support indicated
CTCAE v D11X Xersion 5.0 [13] Fever, with or without
constitutional
symptoms
Hypotension responding to
ﬂuids. Hypoxia responding to
<40% FiO2
Hypotension managed with one
pressor. Hypoxia requiring 40%
FiO2
Life-threatening consequen-
ces; urgent intervention
needed
Lee cD12X Xriteria [14] Symptoms are not life-
D13X Xthreatening and require
symptomatic treatment
only (fever, nausea,
fatigue, headache, myal-
gias, malaise)
Symptoms require and
respond to moderate
intervention:
Symptoms require and respond to
aggressive intervention:
Life-threatening symptoms:
 Oxygen requirement <40%
FiO2 OR
 Oxygen requirement 40% FiO2
OR
 Requirement for ventilator
support OR
 Hypotension responsive to i.
v. D14X Xﬂuids or low dose of one
vasopressor OR
 Hypotension requiring high- D15X Xdose
or multiple vasopressors OR
 Grade 4 organ toxicity*
(excluding transaminitis)
 Grade 2 organ toxicity*  Grade 3 organ toxicity* or grade
4 transaminitis
Penn c D16X Xriteria [17] Mild reaction: Treated
with supportive care,
such as antipyretics,
antiemetics
Moderate reaction: Some signs
of organ dysfunction (grade 2
creatinine or grade 3 LFTs)
related to CRS and not attrib-
utable to any other condition.
More severe reaction: Hospitaliza-
tion required for management of
symptoms related to organ dys-
function, including grade 4 LFTs or
grade 3 creatinine, related to CRS
and not attributable to any other
condition D17X X
Life-threatening complica-
tions such as hypotension
requiring high-dose
vasopressorsD18X X
Hospitalization for manage-
ment of CRS-related symp-
toms, including neutropenic
fever and need for i.v.D19X Xthera-
pies (not including ﬂuid resus-
citation for hypotension)
Hypotension treated with multiple
ﬂuid boluses or low-dose
vasopressors D20X X
Hypoxia requiring mechani-
cal ventilation D21X X
Coagulopathy requiring fresh fro-
zen plasma, cryoprecipitate, or
ﬁbrinogen concentrate D22X X
Hypoxia requiring supplemental
oxygen (nasal cannula oxygen,
high-ﬂow oxygen, CPAP, or BiPAP) D23X X
MSKCC cD24X Xriteria [16] Mild symptoms requir-
ing observation or sup-
portive care only (eD25X Xg D26X X,
antipyretics, antiemet-
ics, pain medication) D27X X
Hypotension requiring any
vasopressors <24 h D28X X
Hypotension requiring any vaso-
pressors 24 h D29X X
Life-threatening symptoms
Hypoxia or dyspnea requiring
supplemental oxygen <40%
Hypoxia or dyspnea requiring sup-
plemental oxygen 40%
Hypotension refractory to
high dose vasopressors
Hypoxia or dyspnea requir-
ing mechanical ventilation
CARTOX c D30X Xriteria [12] Temperature D31X X 8°C Hypotension responds to IV
ﬂuids or low-dose vasopressor
Hypotension needing high-dose or
multiple vasopressors
Life-threatening
hypotension
Grade 1 organ toxicityy Hypoxia requiring FiO2 < D32X X40% Hypoxia requiring FiO2 40% Needing ventilator support
Grade 2 organ toxicityy Grade 3 organ toxicityy or grade 4
transaminitis
Grade 4 organ toxicityy
except grade 4 transaminitis
NSAIDs indicates nonsteroidal anti-inﬂammatory drugs; D33X XLFTs, l D34X Xiver function tests;D35X XBiPAP, b D36X Xilevel positive airway pressure.
* As per CTCAE v D37X Xersion 4.03.
y Cardiac (tachycardia, arrhythmias, heart block, low ejection fraction), r D38X Xespiratory (tachypnea, pleural effusion, pulmonary edema), gastrointestinal D39X X(nausea, vom-
iting, diarrhea), h D40X Xepatic (increased serum alanine aminotransferase D41X X, aspartate aminotransferase D42X X, D43X Xbilirubin level D44X X), r D45X Xenal (acute kidney injury, increased serum creati-
nine, decreased urine output), D46X Xdermatologic D47X X(rash), or c D48X Xoagulopathy (disseminated intravascular coagulation).
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376those who require high-D358X Xdose or multiple vasopressors, a key
difference accounted for by the grading criteria.
Likewise, the grading schema distinguished between
those patients who require minimal oxygen supplementa-
tion and those who requir D 3 59 X Xe aggressive supplementation or
continuous positive airway pressure D 3 6 0X X(CPAP) support. A D 3 6 1X X frac-
tion of inspired oxygen (FiO2 D 36 2X X) of 40% was arbitrarily chosen
as the dividing line between g D 36 3X Xrade D 3 6 4X X2 and grade 3 CRS. D 3 65 X XThisaspect of the deﬁnition D 3 6 6X Xis problematic, however, because
D 3 6 7X Xdelivery of oxygen to patients [14] will vary signiﬁcantly
from hospital to hospital, from patient to patient, and from
shift to shift. Similar to patients requiring low-dose versus
aggressive vasopressor support, patients requiring minimal
oxygen supplementation are distinct in terms of severity
from those who require more aggressive intervention, rang-
ing from CPAP to intubation.
ARTICLE IN PRESS
4 D.W. Lee et al. / Biol Blood Marrow Transplant&& (2018)&&&&&&
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506OTHER GRADING SCHEMES FOR CRS
The Lee criteria have been widely adopted by many CAR T
cell groups, in particular D368X Xbecause D369X Xit was the ﬁrst to link a spe-
ciﬁc gradD370X Xe to a suggested treatment algorithm. The group at
Memorial Sloan Kettering Cancer Center (MSKCC) identiﬁed
objective factors that distinguished severe versus nonD371X Xsevere
CRS in their early clinical trials; however, this relies on the
availability of serum cytokine levels in patients in real D372X Xtime
[15]. Recognizing that assays for serum cytokines are not read-
ily available at most centers, thereby limiting the utility of this
approach, MSKCC redeﬁned the CRS grading used in their clini-
cal trials (Table 1) [16]. Hypotension requiring <D373X X24 hours of
vasopressor use was deemed g D374X Xrade 2, whereas D375X X24 hours of
vasopressor use D376X Xdeﬁnes gD377X Xrade 3, and hypotension not cor-
rected with high-dose vasopressor within 3 hours deﬁnes D378X X
gD379X Xrade 4. Hypoxia also contributes to CRS grading, with a
required FiO2 of 40% serving as the demarcating line between
gD380X XradeD381X X2 and grade 3. Intubation triggers g D382X Xrade 4, but there is
no mention of other methods of delivering positive pressure,
such as CPAP.
The University of Pennsylvania published a grading scale
that has been used in their CD19 CAR T cell trials (Penn criteria;
Table 1) [17]. In contrast to the Lee criteria, the Penn criteria
assign the same grade 3 CRS to patients requiring any amount
of IVF for hypotension and D383X Xpatients requiring low-D384X Xdose vaso-
pressors, and to patients requiring minimal oxygen supple-
mentation and those requiring more aggressive support,
including CPAP. Owing to these differences and the inclusion
of neutropenic fever as a trigger for gD385X Xrade 2 CRS, the Penn cri-
teria tend to assign a higher grade of CRS compared D386X Xwith the
Lee criteria, hinderD387X Xing comparisons of clinical trial safety data
across centersD388X X.
Most recently, a multi-institutional group of investigators
on several industry-sponsored CAR T cell trials published a
manuscript on CAR D389X Xtoxicity (CARTOX) grading and manage-
ment of CRS and CAR-associated neurotoxicity [12]. The CAR-
TOX CRS grading differs slightly from the Lee criteria by
including grade 1 organ toxicity to be considered under grade
1 CRS and deﬁn D390X Xing fever, hypotension, and hypoxia for grading
of CRS in adults (Table 1). In addition, a separate system was
proposed for grading of neurotoxicity. Differences among D391X Xthe
Penn, MSKCC, CARTOX, and Lee approaches to D392X XmanagingD393X XCRS
are outside the scope of the present discussion.
EFFORTS TO HARMONIZE IMMUNE EFFECTOR CELL-
ASSOCIATED CRS AND NEUROTOXICITY DEFINITIONS AND
GRADING
Recognizing the disparity in published grading schemeD394X Xs
and the need for harmonization of deﬁnitions and grading sys-
tems for immune effector cell-associated CRS and neurotoxic-
ities seen after immune effector cell therapies including CAR T
therapy, 49 experts from all aspects of the ﬁeld met in Arling-
ton, VA on June 20-21, 2018, at a meeting supported by the
American Society for Blood and Marrow Transplantation
(ASBMT). Attendees included leaders from major academic
centers involved in CAR T cell therapy research as well as rep-
resentatives from industry, the Center for International Blood
andMarrow Transplant Research (CIBMTR), the American Soci-
ety of Hematology (ASH), and the National Cancer Institute
(NCI). Key presentations regarding immune effector cell-
associated CRS and neurotoxicity were followed by focused
discussion of salient points. The writing group was then tasked
with generating language encompassing a new consensus that
is both easily applied at the bedside and easily veriﬁable during
chart reviews. A full, iterative drafting and vetting process wasundertaken. In addition, these guidelines were presented at
the CIBMTR CT Registry Forum on October 25, 2018, for discus-
sion and comment. The participation at this second meeting
included a broad group of multiple stakeholders including
investigators, industry, payors, and ND395X Xational Institutes of
Health and other governmental agencies. HereD396X Xwe report the
consensus and rationale of the group as related to grading and
reporting of toxicities.
IS D397X XCYTOKINE RELEASE SYNDROME THE APPROPRIATE TERM
FOR IMMUNE EFFECTOR CELL-ASSOCIATED TOXICITY?
We ﬁrst discussed whether “cytokine release syndrome” is
the most appropriate term to assign to the constellation of
symptoms occurring after CAR T cell and other immune effec-
tor cell therapies. The pathophysiology of the syndrome is
unclear, because no animal models of CRS existed until
recently [18,19]. In patients, most CD19 CAR T cell clinical trials
to date have found marked inﬂammatory cytokine elevations
in association with the onset of symptomatology and degree of
severity. In addition, rapid clinical stabilization is frequently
seen with D398X Xuse of the IL-6 receptor antagonistD399X X tocilizumab,
strongly implicating cytokines, especially IL-6 [8,20-22]D400X X, in the
pathophysiology of the syndrome. In the absence of data sug-
gesting an alternative mechanism, we conclude that CRS is the
most appropriate term for these immune effector cell-associ-
ated symptoms and signsD401X X. We recognize that as CAR T and
other immune effector cell therapies are successfully adapted
to treat both hematologic malignancies and solid tumors, addi-
tional or alternative mechanisms of toxicity may be found.
DEFINITION OF CD402X XRD403X XSD404X X
The CTCAE v4.03 deﬁnes CRS as “a disorder characterized
by nausea, headache, tachycardia, hypotension, rash, and
shortness of breath; it is caused by the release of cytokines
from the cells [11].” AlD405X Xthough inclusive of many of the features
of immune effector cell-associated CRS, this deﬁnition does not
include fever, the hallmark of immune effector cell-associated
CRS. D406X XCTCAE v5.0 reﬁned the deﬁnition asD407X X“a disorder character-
ized by fever, tachypnea, headache, tachycardia, hypotension,
rash, and/or hypoxia caused by the release of cytokines [13].”
AltD408X Xhough thD409X Xis list of associated symptoms is more in line with
what is seen clinically during immune effector cell-associated
CRS, this deﬁnition limits the cause to cytokines alone and is
not contextually deﬁned. For example, in bacterial sepsis, high
levels of many cytokines are produced, and symptoms such as
fever and hypotension overlap with CRS, but there is no infec-
tion and the overall clinical picture is distinctly different from
immune effector cell-associated CRS.
It is also important to note that CRS is observed not just
with CAR T and other immune effector cell therapies. In addi-
tion to the TGN1412 experience, it has been described in many
patients treated with blinatumomab, a bi-speciﬁc T cell engag-
ing molecule consisting of 2D410X X covalently linked single chain
antibody fragments targeting CD3 on T cells and CD19 on nor-
mal and malignant B cells [23,24]. Preclinical studies suggest
that CRS could be observed with CAR NK cell therapy as well
[25]. Because D411X Xthe same constellation of symptoms has been
observed after treatment with multiple agents each working in
different ways to activate T and/or other immune effector cells,
CRS as we have described it appears to be an immune effector
cell-associated phenomenon. Therefore, we deﬁne CRS as “a
supraphysiologic response following any immune therapy that
results in the activation or engagement of endogenous or
infused T cells and/or other immune effector cells. Symptoms
can be progressive, must include fever at the onset, and may
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636include hypotension, capillary leak (hypoxia) and end organ
dysfunction.” CRS should be applied to any immune effector
cell-D412X Xengaging therapy, not just with CAR T cells. Cytokine pro-
ﬁles with other therapies mD413X Xight not be the same, and this may
have therapeutic implications. As new, effective immunothera-
pies centered around cell types other than T cells are devel-
oped, the deﬁnition may need to be altered.
SYMPTOMS DEFINING CD414X XRD415X XSD416X XMUST BE ATTRIBUTED TO
IMMUNE EFFECTOR CELL ENGAGEMENT
The common symptoms of CRS are not unique to CRS.
Indeed, practitioners must be cautious and exclude other
causes of fever, hypotension, hemodynamic instability, and/or
respiratory distress, such as an overwhelming infection. Bac-
teremia and other infections have been reported concurrent
with and even mistaken for CRS. A reasonable temporal rela-
tionship to the cell therapy must be present. AltD417X Xhough immune
effector cell-associated CRS may have a delayed onset, it rarely
presents beyond 14 days after initiation of therapy. Patients
exhibiting symptoms consistent with CRS presenting outside
this window should be carefully evaluated for other causes.
TOXICITIES EXCLUDED FROM THE DEFINITION OF CRS
As stated before, neurotoxicity is a frequent complication of
CAR T cell and other TD418X Xcell-D419X Xengaging therapies. Unlike the clas-
sic symptoms of CRS, immune effector cell-associated neuro-
toxicities do not usually respond to tocilizumab, which is not
surprising given the observation that i.v.D420X Xtocilizumab adminis-
tration does not generate signiﬁcant levels of the drug in the
cerebrospinal ﬂuid [26]. Given this ﬁnding, along D421X Xwith the pau-
city of mechanistic data, the lack of known CD19 expression in
the CNS, and the propensity for D422X Xneurotoxicities to develop well
after the classic symptoms of CRS have resolved, we conclude
that immune effector cell-associated neurotoxicities should be
excluded from the deﬁnition of CRS.
Despite this, CRS can impact neurotoxicity and complicate
its assessment. High fever and drug therapy can cause delir-
ium. A sedated and/or intubated patient might D423X Xnot be assess-
able for neurotoxicity. As more insight is gained, this D424X Xmay need
to be reevaluated. In the meantime, we recommend the use of
a separate grading scale for immune effector cell-associated
neurotoxicities as described below.
Hemophagocytic lymphohistiocytosis or macrophage acti-
vation syndrome (HLH/MAS) overlaps substantially with CRS,
as illustrated by ferritin elevations seen in many CAR T cell
recipientD425X Xs during CRS [2,12,20,22,27]. D426X XCRS and classic acquired
HLH/MAS have many shared features, and the 2D427X Xentities D428X Xlikely
are not distinct, reﬂecti D429X XngD430X X the activation of the reticuloendo-
thelial system initiated by T cell-mediated inﬂammation. Most
patients with moderate to severe CRS have laboratory results
that meetD431X Xthe classic criteria for HLH/MAS but may or may not
have hepatosplenomegaly, lymphadenopathy, or overt evi-
dence of hemophagocytosis. In addition, refractory HLH/MAS
hasD432X Xbeen described only in rare cases of immune effector cell-
associated CRS [2,28], wh D433X Xereas in the vast majority of patients,
the symptoms (and characteristic elevated cytokines) sugges-
tive of HLH/MAS resolve with CRS resolution [22]. Given this
overlap, and the absence of a need to directly treat HLH/MAS
in most cases, we conclude that HLH/MAS should be excluded
from the deﬁnition of CRS. P D434X Xatients may meetD435X Xsome of the cri-
teria for HLH/MAS after CAR T cell infusion, but this is part of
the CRS. Because of the inability to separate CRS from HLH/
MAS, and because D436X Xgrading of HLH/MAS is not available as a
separate CTCAE term, the group did not see a need to grade
this entity separately.LABORATORY PARAMETERS ARE NOT INCLUDED IN THE
DEFINITION OR GRADING OF CRS
Signiﬁcant alterations in many laboratory parameters
clearly occur with CRS. Cytokine aberrations have been well
described, but such data are not routinely available in most
academic centers in a time frame that is useful for D437X Xassigning
grade and planningD438X X management of a patient experiencing
CRS. C D439X XRPD440X Xis a widely available and relatively inexpensive labo-
ratory test and initially appeared to be a useful biomarker of
CRS. However, CRP is not speciﬁc for CRS, several scales of
measurement exist, and our experience suggests that changes
in CRP lag behind clinical changes by at least 12 hours. For
these reasons, although D441X XCRP is often used to follow inﬂamma-
tion, we excluded the use of laboratory parameters from the
deﬁnition and grading of CRS and favor a systemD442X Xbased on clin-
ical observation D443X X; however, we do encourage the continued
measurement of cytokines, CRP, ferritin, and other parameters
so that additional data may be generated for future study.
IMPLICATIONS OF A GRADING SYSTEM BASED ON
PRACTITIONER INTERVENTION
Hospitals have varying capacities and policies for providing
escalating care to their patients experiencing serious complica-
tions. Our proposed schema separates grade of CRS basedD444X X
D445X Xlarge D446X Xly on the degree or type of intervention administered to a
patient, for example, i.v.D447X Xﬂuid versus vasopressor use for man-
aging hypotension or admission to the intensive care unitD448X X.
There are several circumstances D449X X (eg,D450X X % oxygen sup-
plementation;D451X Xsee below)D452X X in which D453X Xstrict deﬁnitions are con-
founded by wideD454X X variability in clinical practice. In the end,
many deﬁnitions D455X Xin use reﬂect the treatment decisions made
by the clinical team at the bedside. There was some concern
that some practitioners might alter their usual practice and
rely longer on i.v.D456X Xﬂuids for hypotension and/or delay transfer
to the intensive care unitD457X X in an effort to prevent upgrading a
patient. Such a practice is not the intent of the grading system
and is strongly discouraged, given that D458X Xprolonged ﬂuid resusci-
tation without pressor use is associated with worse outcome
and because D459X Xearly and aggressive supportive care, early use of
vasopressors, and timely anti-cytokine therapy are D460X Xparamount
to mitigating life-threatening CRS.
CONSENSUS ON CRS GRADING
Grade 1 CRS
We deﬁne gD462X Xrade 1 CRS as fever (38.0°C)D463X Xwith or without
constitutional symptoms (Table 2). The associated constitu-
tional symptoms may be reported in accordance with D464X XCTCAE
v5.0 but do not affectD465X XCRS grade. All CRS grading schemes pro-
posed to date mostly agree on what constitutes grade 1 CRS D466X X;
h D467X Xowever, not all systems include fever as a requirement. The
constitutional symptoms of CRS, such as myalgia, arthralgia,
and malaise, are by themselves nonD468X Xspeciﬁc D469X X;D470X X D471X Xhowever, when
coincident with fever in the expected timeframe, the etiology
of CRS is more likely.
Grade 2 CRS
We deﬁne gD472X Xrade 2 CRS as fever (38.0°C) with hypotension
not requiring vasopressors and/or hypoxia requiring the use of
oxygen delivered by low-ﬂow nasal cannula (D473X X6 LD474X X/minute) or
blow-by. Lee et al [14] D475X Xattempted to separate grading for
patients who require minimal vasopressor support from those
that require intensive vasopressor use (also a feature of the
Penn grading) and those requiring minimal oxygen supple-
mentation from those requiring more aggressive assistanceD476X X.
This was doneD477X X in partD478X X out of concern that intervening with
Table 2
ASBMT CRS Consensus Grading
CRS Parameter Grade 1 Grade 2 Grade 3 Grade 4
Fever* Temperature 38°C Temperature 38°C Temperature 38°C Temperature 38°C
With D49X X
Hypotension None Not requiring
vasopressors
Requiring aD50X Xvasopressor with or
without vasopressin
Requiring multiple vasopressors
(excluding vasopressin)
And/ory
Hypoxia None Requiring low-ﬂow
nasal cannulaz or
blow-by
Requiring high-ﬂow nasal cannulaz,
facemask, non D51X Xrebreather mask, or
Venturi mask
Requiring positive pressure (eg, D52X X
CPAP, BiPAP, intubation and
mechanical ventilation)
Organ toxicities associated with CRS may be graded according to CTCAE v5.0 but they do not inﬂuence CRS grading.
* Fever is deﬁned as temperature 38°C not attributable to any other cause. In patients who have CRS then receive antipyretics or anticytokine therapy such as
tocilizumab or steroids, fever is no longer required to grade subsequent CRS severity. In this case, CRS grading is driven by hypotension and/or hypoxia.
y CRS grade is determined by the more severe event: hypotension or hypoxia not attributable to any other cause. For example, a patient with temperature of 39.5°
C, hypotension requiring 1 vasopressor, and hypoxia requiring low-ﬂow nasal cannula is classiﬁed as grade 3 CRS.
z Low-ﬂow nasal cannula is deﬁned as oxygen delivered at 6 L/minute. Low ﬂow also includes blow-by oxygen delivery, sometimes used in pediatrics. High-ﬂow
nasal cannula is deﬁned as oxygen delivered at >6 L/minute.
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766antiD479X Xcytokine therapy such as tocilizumab, as well as early, pro-
longed, or high-D480X Xdose corticosteroids, would abrogate the anti-
D481X Xtumor response. AltD482X Xhough prospective clinical trials evaluating
the timing of intervention are lacking, retrospective analyses
suggest that this is not the case, at least when such therapies
are implemented after CRS is well under way [2,21]. How the
use of preemptive or prophylactic tocilizumab or corticoste-
roids affect the antiD483X Xtumor response or alter the natural history
of other immune effector cell-associated toxicities, such as
neurotoxicity, remains an open question that merits further
D484X XexplorD485X XationD486X Xin well-controlled studies.
The trend D487X Xin many groups has been to move toward the use
of D488X XantiD489X Xcytokine therapy earlier in the development of severe
CRS rather than later. For example, many investigators will
administer tocilizumab with any vasopressor requirement,
even low-dose, or with a signiﬁcant oxygen requirement, rep-
resenting a shift in the treatment algorithm initially proposed
by Lee et al D490X X[12,14], as well as much of the early Penn experi-
ence. In general, we agree with this approach because D491X Xit ini-
tiates CRS management earlier, allowing for earlier resolutionD492X X
while still preserving efﬁcacy. We also differentiate this prac-
tice shift from the prophylactic or preD493X Xemptive use of tocilizu-
mab, which remains experimental. NonethelessD494X X, the goal of the
work was D495X Xto deﬁne a grading system, and the group clearly
recognized the reality of and need for variations in practice in
initiating and escalating CRS treatment.
Despite this shift towardD496X Xearlier intervention, we recognize
there is a distinct difference between patients requiring low-
dose vasopressor or minimal oxygen supplementation and
those who require more aggressive interventions. We sought
to capture this difference in our CRS grading scheme, because
D497X Xsigniﬁcantly less D498X Xresources are needed to support the former
compared D499X Xwith the latter. Our scheme is also aligned with the
general concept in the CTCAE that toxicities requiring speciﬁc
intervention D500X X (eD501X XgD502X X, antiD503X Xcytokine therapy)D504X Xmeet the criteria for
gD505X Xrade 3 at least. However, it is important to recognize that
fever m D506X Xight not always be present concurrently with hypoten-
sion or hypoxia because D507X Xit may be masked by such interven-
tionsD508X X as antipyretics, antiD509X Xcytokine therapy, and/or
corticosteroids, whD510X Xereas hypotension and hypoxia may take
longer to resolve.
Grade 3 CRS
We deﬁne gD511X Xrade 3 CRS as fever (38.0°C) with hypotension
requiring 1D512X X vasopressor with or without vasopressin and/or
hypoxia requiring high-ﬂow nasal cannula (>D513X X6 L D514X X/minute),facemask, nonD515X Xrebreather mask, or venturi mask not attribut-
able to any other cause. Several key features of these criteria
merit D516X Xdiscussion.
The Lee and Penn criteria relied on established deﬁnitions
of low-dose versus high-dose vasopressor use in deﬁning
lower-grade versusD517X Xhigher-D518X Xgrade CRS [14,17]. Although D519X Xthese
deﬁnitions are well accepted in the critical care literature, they
are cumbersome in practice when assigning or auditing CRS
grade. The MSKCC criteria used duration of any vasopressor
dose for less than or greater than 24 hours as differentiating
between grades 2 and 3 CRS [16]D520X X; h D521X Xowever, thD522X Xat arbitrary time
point m D523X Xight not accurately distinguish patients requiring mini-
mal versus signiﬁcant critical care support. As a result, and
owing to real differences in severity between patients requir-
ing 1D524X Xvasopressor D525X Xversus 2D526X Xor more vasopressors, we use this
distinction (1 vD527X Xersus 2 D528X Xvasopressors) in our proposed grading
system.
Many critical care practitioners administer vasopressin
simultaneously with any dose of norepinephrine to capitalize
on its vasoconstrictive effects in an effort to mitigate capillary
leak and minimize norepinephrine dose requirements. The u D529X Xse
of vasopressin in this setting is not in response to escalating
toxicity, so our grading scheme is agnostic to its use. There was
also discussion regarding the inotrope milrinone, which is
often used to aid in contractility and does not escalate the
grade of CRS.
Although previous D530X Xversions of CRS grading relied on captur-
ing the D531X XFiO2D532X X value required to maintain normoxia, this data
point can ﬂuctuate from hour D533X Xto D534X Xhour, making interpretation
and auditing data difﬁcult. To remedy this problem, we elected
to separate grade of CRS due to hypoxia by the device used to
deliver D535X Xoxygen; fD536X Xor example, a sD537X Ximple, low-ﬂow nasal cannula
( D538X X6 LD539X X/minute)D540X X D541X Xis considered gD542X Xrade 2, whereasD543X Xhigh-ﬂow devi-
ces are gD544X Xrade 3. This distinction serves as a surrogate for the
severity of oxygenation deﬁcit.
What constitutes hypoxia D 5 45 X X—or, more accurately, what
oxygen saturation is sufﬁciently low or what clinical signs
are sufﬁcient to warrant supplemental oxygen D 54 6X X—varies
widely across D 5 4 7X X centers, among nursing practice, and accord-
ing to patient age. Normalizing all centers to a single set of
criteria is an exceedingly difﬁcult task. For similar reasons,
we cannot dictate criteria for which supplemental oxygen
is no longer needed in all situations. Therefore, we allow
practitioner discretion and recommend that grading D 54 8X Xbe
determined by the minimal oxygen delivery device
D 5 4 9 X Xrequired to correct the perceived deﬁcit(s).
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We deﬁne gD550X Xrade 4 CRS as fever (38.0°C) with hypotension
requiring multiple vasopressors (excluding vasopressin) and/
or hypoxia requiring positive pressure (eg,D551X XCPAP, bilevel posi-
tive airway pressureD552X X, intubation, D553X Xmechanical ventilation) not
attributable to any other cause. Irrespective of total cumulative
dose, the use of D554X Xmultiple vasopressorsD555X Xconstitutes gD556X Xrade 4 CRS.
An exception for vasopressin is again made, based on the fore-
going reasoningD557X X. Outside of vasopressin, adding a second agent
is a strong indication that the patient remains hemodynami-
cally unstable after the ﬁrst intervention. Such a scenario
would be consistent with grade 4 CRS.
As CRS progresses, capillary leak often leads to pulmonary
edema and impairment of ventilation in addition to oxygen-
ation. These patients tend to respond to positive pressure ven-
tilation, which may be accomplished in several ways, up to
and including intubation and mechanical ventilation. Any use
D558X Xof positive-pressure ventilation constitutes a gD559X Xrade 4 CRS.
Intubation may be indicated in patients who have a degree
of neurotoxicity where there is concern for their ability to
maintain a patent airway. This may occur either in the setting
of CRS or after CRS has resolved. The severity of the neurotox-
icity driving the decision for intubation will be captured by the
grading of that neurotoxicity and should not be captured again
as a gD560X Xrade 4 CRS when the other criteria for such are not met.
In other words, intubation of a patient without hypoxia for the
possible neurologic compromise of a patent airway alone or
for a procedure is not, by deﬁnition, gD561X Xrade 4 CRS. By extension,
a patient experiencing D562X Xseizures in which D563X Xa compromised air-
way affects oxygenation an D564X Xd intubation reverses such deﬁcits
is not considered to have grade 4 CRS, because D565X Xthe seizure
rather than CRS is the cause of the hypoxia. Furthermore, a
patient who remains intubated for a neurologic cause is not
considered to have CRS when the other signs of CRS have
resolved.867
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By convention, gD566X Xrade 5 CRS is deﬁned as death due to CRS in
which D567X Xanother cause is not the principle factor leading to this
outcome.874
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896CRS SEVERITY IS DETERMINED BY HYPOTENSION AND
HYPOXIA
The clinical manifestations of CRS are varied and frequently
involve multiple organ systems. Arrhythmia, cardiomyopathy,
prolonged QTc, heart block, renal failure, pleural effusions,
transaminitis, and coagulopathy are but a few of the signiﬁcant
complications of CRS. Although it is D568X Ximportant to document all
adverse events experienced by CAR T cell recipientD569X Xs, we deter-
mined that such signiﬁcant events are uncommon in the
absence of D570X Xsigniﬁcant hypotension, hypoxia, or both. More-
over, these organ dysfunctions are usually managed symptom-
atically in accordance withD571X X standard guidelines and do not
inﬂuence the decision to use CRS-speciﬁc interventions, such
as antiD572X Xcytokine therapy and corticosteroids. ThusD573X X, hypotension
and hypoxia are the principle determinants of our consensus
grading scale. For these reasons, and to simplify reporting,
references to other speciﬁc organ toxicities have been removed
from CRS grading. However, organ toxicities associated with
CRS may be graded according to CTCAE (currently v5.0) and
reported as required.DEFINITION OF FEVER, HYPOTENSION, AND HYPOXIA AS
RD574X XELATEDD575X XTO CRS GRADING
Fever is deﬁned in the CTCAE v5.0 as “a disorder character-
ized by elevation of the body's temperature above the upper
limit of normal,” and a temperature 38.0 °C is considered
grade 1 fever [13]. We propose to use this same deﬁnition to
deﬁne fever associated with CRS.
The CARTOX criteria deﬁned hypotension as a systolic
blood pressure (SBP) <D576X X90 mmHg in adults, wh D577X Xereas other CRS
grading scales did not speciﬁcally deﬁne hypotension
[11-14,17]. However, an SBP of 80 to D578X X90 mmHg is considered
normal in many children. We also noted that some base the
deﬁnition of hypotension on SBP, whereasD579X X others consider
only D580X Xthe mean arterial pressure (MAP). Both are acceptable
and can be used to determine CRS grade. Therefore, hypoten-
sion should be determined on a case-by-case basis, accounting
for age and the patient’s individual baseline. Indeed, hypoten-
sion is deﬁned in CTCAE v5.0 as “a disorder characterized by a
blood pressure that is below the normal expected for an indi-
vidual in a given environment” [13]. For practical purposes of
CRS grading, an individual requiring IVF boluses or vasopres-
sors to maintain normal blood pressure may be considered to
have hypotension.
Hypoxia is another term that is not deﬁned consistentlyD581X X.
The CTCAE v5.0 deﬁnes hypoxia asD582X X “a disorder characterized
by a decrease in the level of oxygen in the body [13],” but does
not speciﬁcally deﬁne what level of decrease is considered
D583X Xabnormal or even how to measure itD584X X. In fact, most physicians
cannot agree. Many consider hypoxia as an oxygen saturation
(SaO2) <D585X X94% or even 88%, wh D586X Xereas others base it on other
measurements, such as the partial pressure of arterial oxygen.
For CRS grading, an individual requiring supplemental oxygen
to correct a deﬁcit in oxygenation is considered to have hyp-
oxia. Oxygen provided only as a comfort measure D587X Xshould not
be used to inform CRS grade.
DEFINITION OF CRS RESOLUTION
Although D588X Xmost centers are comfortable deﬁning the onset
and grade of CRS at its presentation, there is less clarity about
D589X Xwhen CRS is consideredD590X Xresolved. This is due in large part D591X Xto
anti D592X Xcytokine therapies that dramatically and effectively treatD593X X
fever. TemperatureD594X Xoften normalizesD595X Xwithin a few hours after
D596X Xtocilizumab administration, whereas D597X Xthe other components of
CRS take longer to resolve. Our deﬁnition and grading of CRS
requireD598X X fever. AntiD599X Xcytokine therapies are D600X Xindicated only for
patients with CRS, that is,D601X Xpatients who D602X Xhave fever and meet
the deﬁnition of CRS. Once such therapies are usedD603X X, the patient
is considered to still have CRS, even in the absence of fever,
until all signs and symptoms leading to the diagnosis of CRS
have resolved. Likewise, CRS can be downgraded in an afebrile
patient treated with antiD604X Xcytokine therapy as their hemody-
namic status and/or hypoxia improves. Typically, a patient
with severe CRS in whom fever, oxygen, and pressor require-
ments have resolved may be assumed to have resolved CRS
unless there are alternative causes for the fever, hypoxia, and/
or hypotension. Any neurotoxicity occurring concurrent with
or subsequent to the period of CRS does not inform the grade
of CRS but is instead captured separately in the neurotoxicity
scale.
SYMPTOMS OF D605X XICANSD606X X
Symptoms of ICANS (Table 3) have come into better focus
through early clinical trials and to date have generally been
graded using CTCAE. Although symptoms can be more diverse
than those of D607X XCRS, many patients with neurotoxicity have a
Table 3
Neurologic and Psychiatric Adverse Reactions Reported wD53X Xith Approved CAR T Products D54X X
T D55X Xisagenlecleucel (Kymriah) A D56X Xxicabtagene ciloleucel (Yescarta)
H D57X Xeadache: D58X Xincludes headache and
migraine
ED59X Xncephalopathy: D60X Xincludes D61X Xencephalopathy, cognitive disorder, confusional state, depressed level of consciousness,
disturbed D62X Xattention, hypersomnia, leukoencephalopathy, memory impairment, mental status changes, paranoia,
somnolence, stupor
E D63X Xncephalopathy: D64X Xincludes D65X Xencephalopa-
thy, cognitive disorder, confusional state,
depressed level of consciousness, distur-
bance in attention, lethargy, mental sta-
tus changes, somnolence, and
automatism
HD66X Xeadache tremor dizziness: D67X Xincludes D68X Xdizziness, presyncope, syncope
D D69X Xelirium: D70X XincludesD71X Xdelirium, agitation,
hallucination, hallucination visual, irrita-
bility, restlessness
A D72X Xphasia: includes aphasia, dysphasia motor dysfunction
A D73X Xnxiety D74X Xsleep disorder: D75X XincludesD76X Xsleep
disorder, insomnia, D77X Xnightmares
D78X X elirium: D79X Xincludes D80X Xagitation, delirium, delusion, disorientation, hallucination, hyperactivity, irritability, restlessness
MD81X Xotor dysfunction: D82X Xincludes D83X Xmuscle spasms, muscular weakness, ataxia, seizure, dyscalculia myoclonus
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1016stereotypic D608X Xevolution of a speciﬁc set of symptoms. The earliest
manifestations of ICANS are tremor, dysgraphia, mild difﬁculty
with expressive speech (D609X Xespecially in naming objects),
impaired attention, apraxia, and mild lethargy. Headache is a
nonD610X Xspeciﬁc symptom, frequently occurring during fever or
after chemotherapy in patients without other neurologic dys-
function. Thus, headache alone is not a useful marker of ICANS.
Expressive aphasia, on the other hand, appears to be a very
speciﬁc symptom of ICANS. A D611X XPhase I clinical trial identiﬁed
D612X Xexpressive aphasia asD613X Xthe most characteristic feature, develop-
ing in 19 of 22 patients who went on to develop severe neuro-
toxicity [29]. Expressive aphasia, starting as impaired naming
of objects, paraphasic errors, hesitant speech, and verbal per-
severation, may progress to global aphasia, characterized by
expressive and receptive difﬁculty. Patients with global apha-
sia may appear wide awakeD614X Xbut are mute and unable to follow
commands (akinetic). Many patients have myoclonus or
tremor and increased tone. There may be depressed level of
consciousness with mild lethargy progressing to obtundation,
stupor, or even coma. Mild symptoms may wax and wane with
fever initially only to recur a few days later after CRS has
resolved.
The tempo of progression to severe neurotoxicity may be
hours or days. Subclinical electrographic or clinical seizures
D615X Xmay then develop, accompanied in some cases by motor weak-
ness. When seizures occur, it is often after the development of
severe (global) aphasia. In rare cases, diffuse cerebral edema
develops, in some cases after seizures have occurred, but more
often cerebral edema may have fulminant onset and few ante-
cedent clinical warning signs, suggesting that it may have a
distinct pathophysiology from more reversible neurotoxicity.
There appears to be variability in the presentation of neurotox-
icity with different CAR products. Nevertheless, there has
been progress toward understanding and deﬁning relevant
D616X Xsigns and symptoms of neurotoxicity in the progression
toward severe toxicity that might trigger intervention in the
acute setting.1017
1018
1019
1020
1021
1022
1023
1024
1025
1026DEFINITION OF ICANSD617X X
Neurologic symptoms may be observed in association with
pathological processes including hepatic failure, severe hyper-
tension, eclampsia, infection, electrolyte abnormalities, and
immunosuppressive and cytotoxic drug therapies. ICANS may
have features that overlap with other encephalopathies but
has the more speciﬁc characteristic of an awake patient who is
mute and does not respond verbally or physically to anexaminer. ICANS may have a unique pathophysiology com-
pared D618X Xwith D619X Xother encephalopathies. In a recent report, Gust
et alD620X X [30] suggested a role for endothelial activation and
blood-brain barrier disruption in the pathophysiology of
neurotoxicityD621X X. Another report found elevated levels of the
excitatory NMDA receptor agonists glutamate and quinolinic
acid in cerebrospinal ﬂuid from patients with neurotoxicity
[26]. Several reports suggest a role for proD622X Xinﬂammatory cyto-
kines and myeloid cells besides activated T cells [2,18,29,31-
33]. The term CAR-related encephalopathy syndrome (CRES)
has been proposed to describe neurotoxicity associated with
CAR T cell therapy [12]. We acknowledge that encephalopathy
is a dominant feature of the neurologic changes that occur;D623X X
however, we prefer the term ICANS D624X Xto be inclusive of other
symptoms, as well as to acknowledge other cellular immuno-
therapies and therapeutics, such as bispeciﬁc antibodies, that
may have similar neurologic side effects. We deﬁne ICANS as
“a disorder characterized by a pathologic process involving the
central nervous system following any immune therapy that
results in the activation or engagement of endogenous or
infused T cells and/or other immune effector cells. Symptoms
or signs can be progressive and may include aphasia, altered
level of consciousness, impairment of cognitive skills, motor
weakness, seizures, and cerebral edema.” Similar to CRS, ICANS
should be applied to any immune effector cell engaging ther-
apy, not just CAR T cells.SYMPTOMS AND SIGNS EXCLUDED FROM THE DEFINITION
OF ICANSD625X X
Although other neurologic D626X Xsymptoms and/or signs, such as
headache, tremor, myoclonus, asterixis, and hallucinations,
may occurD627X X and possibly be attributable to immune effector
cell- D628X Xengaging therapies, we have excluded them from the deﬁ-
nition of neurotoxicity because D629X Xthey are less speciﬁc, are usu-
ally managed symptomatically, and do not trigger speciﬁc
interventions, such as corticosteroids, to abrogate activation of
T cells and other immune cellsD630X X. Weakness and balance prob-
lems may occur owing D631X Xto deconditioning and loss of muscle
mass from immobility and are frequently seen in the trans-
plantation and intensive chemotherapy setting and are
excluded from the deﬁnition of ICANS. Intracranial hemor-
rhage with or without associated edema may occur due to coa-
gulopathies in these patients and is also excluded. We
recommend that practitioners capture and report such associ-
ated events in accordance with D632X XCTCAE v5.0 [13].
Q3
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1111CONSENSUS ON ICANS GRADING FOR ADULTS
AltD633X Xhough early clinical trials used CTCAE v4.03 for grading
neurotoxicity, further reﬁnement was achieved when a multi-
institutional group of oncologists leading CAR T cell trials
across the United States published the CARTOX criteria for
adults on grading of neurotoxicity. The CARTOX system grades
neurotoxicity by assessing multiple neurologic D634X X domains that
span the constellation of signs and symptoms associated with
neurotoxicity (Table 4). An important development was a 10-
point screening tool called the CARTOX-10, which incorpo-
rated key elements of the Mini-Mental State Examination
(MMSE) to evaluate the alterations in speech, orientation,
handwriting, and concentration thatD635X Xare highly suggestive of
the encephalopathy observed in patients with ICANS (Table 5).
This screening tool was designed to overcome the subjectivity
in grading many overlapping encephalopathy terms, such as
encephalopathy, delirium, aphasia, confusion, and othersD636X X. It
moved away from deﬁning the grade of encephalopathy
according to impairment of ability to perform activities of daily
living, which can be difﬁcult to assess in hospitalized patients.Table 4
Published ND84X Xeurotoxicity G D85X Xrading S D86X Xystems D87X X
Grading System D88X X Adverse
Event Term D89X X/
D90X XNeurotoxicity
Domain
Grade 1
Grade 4
CTCAE v5.0 [13],* Encephalopathy Mild symptoms
Life- D92X Xthreatening
consequences; D93X X
urgent intervention
indicated
Seizure Brief partial seizure
and no loss of
consciousness
Brief generalized seizure
Dysphasia Awareness of recep-
tive or expressive
characteristics; not
impairing ability to
communicate
Moderate receptive or ex
characteristics; impairing
communicate spontaneou
Tremor Mild symptoms Moderate symptoms; lim
instrumental ADL
Headache Mild pain Moderate pain; limiting i
tal ADL
Confusion Mild disorientation Moderate disorientation;
instrumental ADL
Depressed
level of
consciousness Decreased level of alertne
Life- D100X Xthreatening
consequences;
coma; urgent inter-
vention indicated
Cerebral
edema
CARTOX c D101X Xriteria [12] Neurologic D102X X
Assessment
Score (CAR-
TOX-10)
7-9 (m D103X Xild
impairment)
3-6 (m D104X Xoderate impairmen
ElevateD106X Xd ICP D107X X N/A N/A
Seizures or
motor
weakness
N/A N/A
ADL indicates D110X Xactivities of daily living; CSF, D111X Xcerebrospinal ﬂuid; EEG: electroencephalo
* CTCAE: Under CRS listing: “Also consider neurologic toxicities such as psychiatric
phasia, tremor, headache.”
y Papilledema grading is performed according to the Modiﬁed Frisen scale [35].The CARTOX grading system for neurotoxicity also
included evaluation of other domains including level of con-
sciousness, motor symptoms, seizures, and signs of elevated
D 63 7X Xintracranial pressure (ICP) (Table 4). For evaluation of raised
ICP and determination of neurotoxicity grade, the guidelines
suggested using elevated cerebrospinal ﬂuid opening pres-
sure and papilledema grade by the Frisen S D 63 8X Xcale X X (Figure 4).
Unfortunately, these measurements are cumbersome, poten-
tially inaccurate, and difﬁcult to extend to routine practice.
For example, lumbar puncture can be difﬁcult to perform in
critically ill patients, and D 63 9X Xwhen it is done, opening pressure
may vary with age, body habitus, positioning, systemic blood
pressure, mechanical ventilation, and pharmacologic sedation
[34]. In the case of papilledema grading, hospitals have differ-
ing capacities for rapid grading of papilledema, leading to
variable grading (Frisen grade 2 versus D6 4 0X X 3) depending on
the individual performing the examination, use of fundus
photography, and other factors D6 4 1X X.
For our consensus grading scheme, we propose the use of a
slightly modiﬁed version of the CARTOX-10 screening tool,Grade 2 Grade 3
Moderate symptoms; limiting
instrumental ADL
Severe symptoms; limiting
self- D91X Xcare ADL
New- D94X Xonset seizures (partial or
generalized); multiple seizures
despite medical intervention
Life- D95X Xthreatening
consequences
pressive
ability to
sly
Severe receptive or expressive
characteristics; impairing ability
to read, write, communicate
intelligibly
iting Severe symptoms; limiting self-
D96X Xcare ADL
nstrumen- Severe pain; limiting self-D97X Xcare
ADL
limiting Severe disorientation; limiting
self- D98X Xcare ADL
Life- D99X Xthreatening consequen-
ces; urgent intervention
indicated
ss Sedation; slow response to stim-
uli; limiting instrumental ADL
Difﬁcult to arouse
New onset; worsening from
baseline
Life-threatening consequen-
ces; urgent intervention
indicated
t) 0-2 (sD105X Xevere impairment) Patient in critical condition,
and/or obtunded and cannot
perform assessment of tasks
Stage 1-2 papilledemay or CSF
opening pressure <20 mmHg
Stage 3-5 papilledemay, or
CSF opening pressure 20
mmHg, or cerebral edema
Partial seizure or nonD108X Xconvulsive
seizures on EEG with response to
benzodiazepine
Generalized seizures or con-
vulsive or nonD109X Xconvulsive
status epilepticus, or new
motor weakness
graphy D112X X.
disorders: hallucinations or confusion; nervous system disorders: seizure, dys-
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
Table 5
Encephalopathy Assessment Tools fD113X Xor Grading oD114X Xf D115X XICANS D116X X
CARTOX-10 [12] D117X XICE D118X X
D119X XOrientation: oD120X Xrientation to year, month, city, hospital, p D121X Xresident/p D122X Xrime
m D123X Xinister of country of residence: 5 points
D124X XOrientation: oD125X Xrientation to year, month, city, hospital: 4 points
D126X XNaming: ability to n D127X Xame 3 objects (e D128X Xg D129X X, point to clock, pen, button): 3
points
D130X XNaming: ability to n D131X Xame 3 objects (e D132X Xg D133X X, point to clock, pen, button): 3
points
D134X XWriting: a D135X Xbility to write a standard sentence ( D136X Xeg, “Our national bird is
the bald eagle”): 1 point
D137X XFollowing commands: ability to follow simple commands (e D138X Xg D139X X, “Show
me 2 ﬁngers” or “Close your eyes and stick out your tongue”): 1 point
D140X XAttention: ability to c D141X Xount backwards from 100 by 10 D142X X: 1 point D143X XWriting: aD144X Xbility to write a standard sentence (e D145X Xg D146X X, “Our national bird is
the bald eagle”): 1 point
D147X XAttention: ability to cD148X Xount backwards from 100 by 10 D149X X: 1 point
CARTOX-10 (left column) has been updated to the ICE tool (right column). ICE adds a command-following assessment in place of 1D150X Xof the CARTOX-10 orientation
questions. The scoring system remains the same.
Scoring: D151X X 0, n D152X Xo impairment;
D153X X7-9, g D154X Xrade 1 ICANS;
D155X X3-6, g D156X Xrade 2 ICANS;
D157X X0-2,D158X Xgrade 3 ICANS;
D159X X0 due to patient unarousable and unable to perform ICE assessment, g D160X Xrade 4 ICANS.
ARTICLE IN PRESS
10 D.W. Lee et al. / Biol Blood Marrow Transplant&& (2018)&&&&&&
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259D642X Xhere termed the Immune E D643X Xffector Cell-AD644X Xssociated Encephalop-
athy (ICE) sD645X Xcore, to provide objectivity for the grading of multi-
ple overlapping encephalopathy terms currently included D646X Xin
the approved CAR T products (Table 3). The updated encepha-
lopathy screening tool (Table 5) includes an element for
D647X Xassessing the receptive aphasia seen in these patients. The total
number of points, ease of administration, and categorization of
scores remain the same as in the original CARTOX-10 [12]. It is
important to note that the 10-point ICE screening tool is help-
ful for D648X Xassessing patients for encephalopathy; hD649X Xowever, the
grading of ICANS requires assessment of the 10-point ICE score
as well as evaluation of other neurologic D650X Xdomains, such as level
of consciousness, motor symptoms, seizures, and signs of ele-
vated D651X XICP/cerebral edema, which may occur with or without
encephalopathy.
In contrast to CTCAE v4.03, in which D652X Xa generalized seizure
was considered grade 2, our consensus guidelines are more
aligned with CTCAE v5.0, which considers a new seizure of anyTable 6
ASBMT I D161X XCANS D162X XConsensus Grading for Adults
Neurotoxicity Domain Grade 1 Grade 2 Grade 3
ICE sD163X Xcore* 7-9 3-6 0-2
Depressed level of
consciousnessy
Awakens
spontaneously
Awakens to
voice
Awakens only
Seizure N/A N/A Any clinical se
ized that reso
n D165X Xon D166X Xconvulsive
resolve with i
Motor ﬁndingsz N/A N/A N/A
ElevatedD168X XICP D169X X/ D170X Xc D171X Xerebral
edema
N/A N/A Focal/local ed
ICANS grade is determined by the most severe event (ICE score, level of consciousne
other cause; fD172X Xor example, a patient with an ICE score of 3 who has a generalized seizur
N/A indicates not applicable.
* A patient with an ICE score of 0 may be classiﬁed as D175X Xgrade 3 ICANS if D176X Xawake with
ICANS if D179X Xunarousable.
y Depressed level of consciousness should be attributable to no other cause (e D180X Xg D181X X, no s
z Tremors and myoclonus associated with immune effector cell therapies may be gr
x Intracranial hemorrhage with or without associated edema is not considered a
according to CTCAE v5.0.type as grade 3 and any life-threatening seizure as grade 4.
Compared D653X Xwith the original CARTOX CRES grading and CTCAE
v5.0, the new consensus grading has been simpliﬁed so that a
single D654X Xclinical or subclinical electrographic seizure of any type
is grade 3 and prolonged or repetitive clinical or subclinical
electrographic seizures without a return to baseline in
between are grade 4 (Table 6). Patients may have electroence-
phalographyD655X Xchanges, such as generalized or frontal slowing or
frontal intermittent rhythmic delta activityD656X X, which D657X Xshould not
be considered seizures.
We have also modiﬁed the criteria for assessment of ele-
vated D658X XICP to improve the ease of grading compared D659X Xwith the
CARTOX CRES grading system by reduc D660X Xing cerebrospinal ﬂuidD661X X
opening pressure and the requirement to grade papilledema
on the modiﬁed Frisen scale [35] (Table 6). This does n D662X Xot
negate the importance of making a clinical assessment to
determine the presence of D663X Xelevated ICP D664X X, but acknowledges that
other signs and symptoms, including simply the presence orGrade 4
0 (patient is unarousable and unable to perform
ICE)
to tactile stimulus Patient is unarousable or requires vigorous or
repetitive tactile stimuli to arouse. Stupor or
coma
izure focal or general-
lves rapidly D164X Xor
seizures on EEG that
ntervention
Life-threatening prolonged seizure (>5 min); or
Repetitive clinical or electrical seizures without
return to baseline in between D167X X
Deep focal motor weakness such as hemiparesis
or paraparesis
ema on neuroimagingx Diffuse cerebral edema on neuroimaging; Decer-
ebrate or decorticate posturing; or Cranial nerve
VI palsy; or Papilledema; or Cushing's triad
ss, seizure, motor ﬁndings, raised ICP/cerebral edema) not attributable to any
e is classiﬁed as D173X Xg D174X Xrade 3 ICANS.
global aphasia, b D177X Xut a patient with an ICE score of 0 may be classiﬁed as D178X Xgrade 4
edating medication).
aded according to CTCAE v5.0, but they do not inﬂuence ICANS grading.
neurotoxicity feature and is excluded from ICANS grading. It may be graded
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1392absence of papilledema taken in conjunction with depressed
level of consciousness, can be used to D665X XmakD666X Xe this assessment.
We have highlighted the importance of evaluating level of con-
sciousness by making it a more detailed factors D667X Xin the grading.
In the grading system, the ﬁnal ICANS grade is determined
by the most severe event among the different domains.
Grade 1 ICANS
We deﬁne gD668X Xrade 1 ICANS as a score of 7 to D669X X on the ICE
assessment (Table 6). A patient with grade 1 ICANS may have a
delay in responseD670X Xor disorientation to time or place, mild inat-
tention with difﬁculty in counting numbers backwardD671X X, or
impairD672X Xed handwriting. There may be drowsiness but the
patientD673X X awakens spontaneously, and when prompted, the
patient should be able to complete most of the ICE assessment.
Grade 1 ICANS may be seen during CRS waxing and waning
with febrile episodes.
Grade 2 ICANS
We deﬁne gD674X Xrade 2 ICANS as a score of 3 to D675X X on the ICE
assessment (Table 6). Patients with grade 2 ICANS often have
some expressive aphasia, limiting the ability to communicate
spontaneously. Patients D676X Xalso may D677X Xhave difﬁculty writing a stan-
dard sentence due to poor handwriting and apraxia. They have
difﬁculty naming objects due to expressive aphasia and/or fol-
lowing commands due to receptive aphasia and poor concen-
tration. In our experience, expressive aphasia is the most
speciﬁc ﬁrst sign of severe neurotoxicity, and early signs D678X Xin D679X X
grade 2 include paraphasic errors (the production of unin-
tended syllables and words during attempts to speak) and ver-
bal perseveration D680X X(repeating the same words over and over).
Patients with grade 2 ICANS are able to communicate their
needs with D681X XeffortD682X X. Patients may have a depressed level of con-
sciousness but are arousable to voice and the responses may
be slowed.
Grade 3 ICANS
We deﬁne gD683X Xrade 3 ICANS as a score of 0 to D684X X2 on the ICE
assessment (Table 6). Patients with grade 3 ICANS have severe
global aphasia and doD685X X not speakD686X X or followD687X X commands even
when wide awake and thuD688X Xs may be unable to answer D689X Xany ofTable 7
Encephalopathy Assessment for Children Age <12 YD182X Xears UD183X Xsing the D184X XCAPD D185X XD186X X
Answer the following based on interactions with the child over
the course of the shift
Never, 4
1. Does the child make eye contact with the caregiver?
2. Are the child’s actions purposeful?
3. Is the child aware of his/her surroundings?
4. Does the child communicate needs and wants?
Never, 0
5. Is the child restless?
6. Is the child inconsolable?
7. Is the child underactive; D187X Xvery little movement while awake?
8. Does it take the child a long time to respond to interactions?
(Adapted from Traube et al [36]; reproduced with permission.)
For patients age 1-2 years, the following serve as guidelines to the corresponding ques
1. Holds gaze, D188X Xprefers primary parent, l D189X Xooks at speaker.
2. Reaches and manipulates objects, tries to change position, if mobile may try to get u
3. Prefers primary parent, upset when separated from preferred caregivers. Comforted
4. Uses single words or signs.
5. No sustained calm state.
6. Not soothed by usual comforting actions, eg D192X X, singing, holding, talking, and reading.
7. Little if any paly, efforts to sit up, pull up, and if mobile crawl or walk around.
8. Not following simple directions. If verbal, not engaging in simple dialog D193X Xwith wordsthe ICE questions. Alternatively, they may have excessive
drowsiness and need tactile stimulus to attend to the exam-
iner. Any clinical seizure, whether simple partial, complex par-
tial, or generalized, and any electrographic seizures would also
meet the criteria for grade 3 ICANS (Table 6). This acknowl-
edges that seizure may be the peak of an excitatory neurotox-
icity process that ﬁrst manifests clinically as progressive
aphasia and then peaks with onset of a clinical or electro-
graphic seizure. If neuroimaging shows new focal or local
edema, this would also be categorized as grade 3 ICANS
(Table 6). However, intracranial hemorrhage due to coagulop-
athy or other causes with or without associated edema is not
considered a neurotoxicD690X X feature and is excluded from ICANS
grading.
Grade 4 ICANS
We deﬁne Grade 4 ICANS as patients who have a score of 0
on the ICE assessment due to being unarousable and unable to
perform the ICE assessment. Stupor and coma may be seen;
the stuporous patient D691X Xresponds only by grimacing or drawing
away from vigorous or repetitive tactile stimuli, and the coma-
tose patient is unarousable and/or unresponsive (Table 6). This
depressed level of consciousness should be attributable to no
other cause (eD692X XgD693X X, no sedating medication), which is often a com-
plicating factor in sick patients with CRS. Some patients may
require intubation for airway protection. In addition, any
patient experiencD694X Xing prolonged or repetitive clinical or sub-
clinical electrographic seizures without a return to baseline in
betweenD695X Xor with deep focal motor weakness, such as hemipa-
resis or paraparesis, would be considered to have g D696X Xrade 4
ICANS (Table 6). Patients with symptoms and signs of elevated
ICP, such as projectile vomiting with headache;D697X Xdepressed con-
sciousness;D698X X cranial nerve VI palsies;D699X X papilledema; D700X X Cushing's
triad of bradycardia, hypertension, and respiratory depression;D701X X
decerebrate or decorticate posturing;D702X X and D703X Xdiffuse cerebral
edema on head imaging, would also be considered to have
grade 4 ICANS (Table 6).
The new grading is similar to the CARTOX CRES grading
guideline in regard to the CARTOX-10 screening assessment, in
that it D704X XclassifD705X Xies any patient too obtunded to perform the
assessment as having grade 4 ICANS. In contrast to CARTOXRarely, 3 Sometimes, 2 Often, 1 Always, 0
Rarely, 1 Sometimes, 2 Often, 3 Always, 4
tions:
p.
by familiar objects (i D190X XeD191X X, blanket or stuffed animal).
or jargon.
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Table 8
ASBMT I D194X XCANS D195X XConsensus Grading for Children
Neurotoxicity Domain Grade 1 Grade 2 Grade 3 Grade 4
ICE sD196X Xcore for children age >12 yr* 7-9 3-6 0-2 0 (patient is unarousable and unable to perform
ICE)
CAPD score for children age 12 y D197X XrD198X X <9 <9 9 Unable to perform CAPD
Depressed level of consciousnessy Awakens
spontaneously
Awakens to voice Awakens only to tactile
stimulus
D199X XUnarousable or requires vigorous or repetitive
tactile stimuli to arouse; D200X Xs D201X Xtupor or coma
Seizure (any age) N/A N/A Any clinical seizure focal or
generalized that resolves
rapidly D202X Xor n D203X Xon D204X Xconvulsive
seizures on EEG that resolve
with intervention
Life-threatening prolonged seizure (>5 min); or
Repetitive clinical or electrical seizures without
return to baseline in between D205X X
Motor weakness (any age)z N/A N/A N/A Deep focal motor weakness, such as hemiparesis
or paraparesis
ElevatedD206X XD207X XICP D208X X/ D209X Xcerebral eD210X Xdema (any age) Focal/local edema on
neuroimagingx
Decerebrate or decorticate posturing D211X X, cD212X Xranial
nerve VI palsy, D213X Xpapilledema, D214X XCushing's triad, D215X Xor
sD216X Xigns of diffuse cerebral edema on neuroimaging
ICANS grade is determined by the most severe event (ICE or CAPD score, level of consciousness, seizure, motor ﬁndings, raised ICP/cerebral edema) not attributable to
any other cause.
* A patient with an ICE score of 0 may be classiﬁed as D217X Xgrade 3 ICANS if D218X Xawake with global aphasia, b D219X Xut a patient with an ICE score of 0 may be classiﬁed as D220X Xgrade 4
ICANS if D221X Xunarousable.
y Depressed level of consciousness should be attributable to no other cause (e D222X Xg D223X X, no sedating medication).
z Tremors and myoclonus associated with immune effector cell therapies may be graded according to CTCAE v5.0, but they do not inﬂuence ICANS grading.
x Intracranial hemorrhage with or without associated edema is not considered a neurotoxicity feature and is excluded from ICANS grading. It may be graded
according to CTCAE v5.0.
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1546CRES, the updated grading classiﬁes an isolated generalized
seizure with return to baseline as g D706X Xrade 3D707X Xand reserves gD708X Xrade 4
classiﬁcation for prolonged >5 minutes or repetitive clinical or
subclinical (electroencephalographyD709X X only) seizures without
return to baseline in between. This is consistent with life-
threatening seizures as deﬁned by CTCAE v5.0.
Grade 4 patients typically need to be intubated for airway
control and seizure management. A patient may be intubated
for grade 4 ICANS, but this should not be recapturedD710X Xas grade 4
CRS when other signs of severe CRS have resolved.
Grade 5 ICANS
By convention, gD711X Xrade 5 ICANS is deﬁned as death due to
ICANS where another cause is not the principle factor leading
to this outcome.
CONSENSUS ON ICANS GRADING FOR CHILDREN
Although D712X Xthe 10-point ICE assessment is useful for screen-
ing adults for encephalopathy, its use in children may be lim-
ited to those age D713X X12 years with sufﬁcient D714X Xcognitive abili D715X Xty to
perform the ICE assessment. For children age <12 years, the
Cornell Assessment of Pediatric Delirium (CAPD) [36,37]
(Table 7) is recommended to aid D716X Xin the overall grading of
ICANS, as recently proposed by Mahadeo et al [38]. A CAPD
score of 9 is suggestive of delirium and should be considered
D717X Xgrade 3 ICANS. The CAPD score also may D718X Xbe used in patients
age >12 years with baseline developmental delay as it has
been validated up to age 21 years. Other domains evaluated to
grade ICANS in children are similar to those used in adults and
include level of consciousness, motor symptoms, seizures, and
signs of raised ICP (Table 8).
DATA COLLECTION AND REPORTING FOR APPROVED CELL
THERAPY PRODUCTS
The h D719X Xigh unmet medical needs and large effect sizes seen in
clinical testing of CD19 CAR T cell therapies allowed approval
of the 2D720X Xcurrent products based on data collected from <300
total patients on 3D721X Xsingle-D722X XarmD723X XPhase II trials. As a result, there
is broad agreement that further data collection on toxicity andpatient outcomes is paramount. The US Food and Drug Admin-
istrationD724X X (FDA) requiresD725X X that pharmaceutical companies that
produce commercial CAR T cell products D726X Xestablish a mecha-
nism to follow recipients of these therapies for 15 years,
although this requirement is D727X Xfocused mainly on monitoring for
potential long-term genotoxicity. Other health authorities may
impose other D728X Xor more detailed requirements.
This raises important questions on how best to collect
appropriate data, especially because D729X Xthese mandates are placed
on the companies but carried out by the centers in a largely
volunteer effort. Compliance with what could be a signiﬁcant
and unfunded mandate will be enhanced by making sure that
data collection is appropriately focused, especially because
D730X Xthese data will not be collected in a research setting with
research budgets and direct regulatory mandates on the cen-
ters. Health authorities will need to harmonize their data
requests. In this new ﬁeld of medicine, companies may have to
face the possibility of a gap between what the FDA or European
Medicines AgencyD731X Xwants them to collect and what centers are
actually able to provide. There needs to be a simpliﬁed and
uniﬁed approach to reporting with a single portal for data
entry. A registry approach is likely to be the best method of
providing as complete data as possible.
The CIBMTR operates a large outcomes database, which for
decades has been a valuable resource for D732X Xthe ﬁeld of transplanta-
tion. Most centers with active immune effector cell programs
have many years of experience using this database. Recognizing
the emergence of the ﬁeld of cellular immunotherapy, in 2016
the CIBMTR launched a database dedicated to cellular therapy
outcomes. This registry tracks long-term follow-up of patients
who have received cellular therapies, including CAR T cells and
other cellular therapies beyond hematopoietic cell transplanta-
tionD733X X. As part of this process, the CIBMTR Cellular Therapy Task
Force developed new reporting forms speciﬁc to cellular therapy
[39], which were subsequently piloted and reﬁned.
Since the launch in 2016, centers voluntarily have reported
data derived from more than 200 recipients of CAR T cells, which
are most commonly used for treatment of non-Hodgkin lym-
phoma and acute lymphoblastic leukemia. Using a single,
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1676standardized database to capture information about recipients of
immune effector cell therapies can streamline the process and can
provide a resource for research. The CIBMTR’s Cellular Therapy
Registry infrastructure is well suited tomeet this requirement.
Regulators in other regions are considering more require-
ments to assess the safety and efﬁcacy of immune effector cell
therapies. The EMA organized a workshop in February 2018 to
identify a minimal set of data elements for commercial CAR T
cells [40]. In addition to common safety endpoints, the EMA
report outlined the capture of gradeD734X X3 and 4 organ toxicities [41].
Lee et al initially included gradeD735X X2 to D736X X4 nonhematologic organ tox-
icities in their CRS grading criteria [14]D737X X; hD738X Xowever, organ toxicities
are excluded in the new CRS consensus grading scheme pro-
posed here. Requiring reporting of organ toxicities in the post-
D739X Xmarket setting would add a considerable burden for data
collection, and it runs the risk of being infeasible. This example
highlights the need for harmonization in the data requested.
The CIBMTR Cellular Therapy Registry’s follow-up form
captures toxicities after immune effector cell infusion, at 3
months, 6 months, 1 year, and yearly thereafter. The outcomes
routinely captured in the CIBMTR follow-D740X Xup forms relevant to
CAR TD741X X cell toxicities include CRS, neurotoxicities, neutrophil
and platelet recovery, hypogammaglobulinemia, severe infec-
tions, nonD742X Xhematologic grade 4 toxicities, and death from any
cause. For CRS, the registry computes a grade by capturing key
information related to CRS, including treatment (eg, D743X Xuse of vas-
opressors). This approach can accommodate changes in the
grading criteria, as proposed in this consensus statement, or
comparisons across grading systems. For ICANS, the forms cap-
ture the presence of different manifestations, and whether
they resolved. Issues raised on the applicability of CTCAE to
assess severity in hospitalized patients apply here as well.
Beyond the abovementioned toxicities, centers can report sub-
sequent neoplasms and pregnancies at any time through
event-driven forms. These forms aid the collection of time-sen-
sitive information or biospecimens, if needed.
We believe that it would be safest and most efﬁcient to use
CIBMTR database reporting to meet the mandates placed on
the drug companies at a level that is feasible for centers offer-
ing immune effector cell therapies outside the research setting.
Barring unusual or notable toxicity that any treating physician
can choose to report to the FDA on a MedWD744X Xatch form (as with
any other approved therapy), we endorse a system in which
the CIBMTR registry is D745X Xa single resourceD746X X that centers can use
for studies of D747X Xcurrent and future approved cell therapies. The
CIBMTR built the Cellular Therapy Registry to serve the com-
munity and to help advance the ﬁeld by making the data avail-
able to investigators. Standardized collection of toxicity data in
the real-world setting will help identify ways to make these
therapies safer.
CONCLUSION
In conclusion, we have proposed consensus deﬁnitions and
grading for CRS and ICANS, the 2 D748X Xmost common toxicities asso-
ciated with immune effector cell therapies. We acknowledge
that as new data becomeD749X X available from existing and novel
immune effector cell therapies, this grading system may need
to be revised in the future. Nonetheless,D750X Xwe believe that D751X Xour
proposed grading system is objective, easy to use, and more
accurately categorizes the severity of these toxicities. We
strongly recommend the us D752X Xe of this consensus grading system
for reporting of CRS and neurotoxicity associated with immune
effector cell-engaging therapies across all clinical trials, as well
as in the postD753X Xapproval standard of care setting. This would
allow comparison of the safety of different immune effectorcell-engaging therapies and D754X Xalso likely facilitate the develop-
ment of optimal strategies for prevention and/or management
of these toxicities.
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